OSX 002
Alternative Names: FAST-LNP gene therapy - Entos Pharmaceuticals/OncoSenX; OSX-002Latest Information Update: 29 Sep 2020
At a glance
- Originator Entos Pharmaceuticals
- Developer Entos Pharmaceuticals; OncoSenX
- Class Antineoplastics; Gene therapies; Immunotherapies; Nucleic acids
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 Sep 2020 Preclinical trials in Cancer in USA (Parenteral) before September 2020 (Entos Pharamceuticals pipeline, September 2020)